The article considers the issue of disorders of connective tissue metabolism in diabetes mellitus. Glycosylation of structural components of connective tissue and glucose toxicity have been found to determine the pathogenesis of late complications of diabetes mellitus. The most common concept of the pathogenesis of diabetes is metabolic, according to which all variants of diabetes mellitus, including blood vessels, their basement membrane, are associated with primary disorders of lipid, glycoprotein, protein and carbohydrate metabolism due to complete or partial insufficiency. It has been found that the formation of interstitial fibrosis in the kidneys of patients with diabetes begins in the preclinical stages of diabetic nephropathy. The leading cause of interstitial fibrogenesis is hyperglycemia; exacerbate proteinuria fibrosis, activation of the renin-angiotensin system, chronic inflammation and the formation of myofibroblasts in the interstitium. According to the results of the study of aspects of early diagnosis of kidney damage in type 1 diabetes mellitus, it was found that the development of diabetic nephrosclerosis is characterized by qualitative and quantitative changes in collagen composition in the glomeruli and interstitium, rebalance between collagen synthesis and breakdown, glycosaminoglycans, increased synthesis of fibrogenic growth factors and oxidative modification of proteins. The formation of diabetic nephropathy in patients with diabetes is also characterized by the accumulation of collagen types IV and VI, the appearance of interstitial collagen types III and I in the glomeruli, as well as the accumulation of collagen of all types in tubulointerstitium. Quantitative and qualitative characteristics of sulfated glycosaminoglycans of urine in human diabetes indicated different degrees of development of diabetic nephropathy. Glycosaminoglycans hyperexcretion was observed in patients with diabetes mellitus without proteinuria. In patients with microalbuminuria, glycosaminoglycans hyperexcretion was even more pronounced. It was also found that in diabetes, the total excretion of sulfated glycosaminoglycans in the urine doubles. Conclusion. Thus, in diabetes mellitus, an important pathogenetic link in the violation of the morpho-functional state of the kidneys is the degradation of collagen and proteoglycans of the basement membranes of the glomeruli, as well as interstitial fibrosis. This is reflected in changes in urinary glycosaminoglycans excretion, in particular heparansulfate and chondroitin sulfate, which may serve as a marker of proteoglycan metabolism disorders in the kidneys. Patients with diabetes also have an increase in the urine of hydroxyproline, which indicates an increase in the intensity of collagen metabolism in patients

Keywords: diabetes mellitus, nephropathy, collagen, proteoglycans, heparansulfate

Full text: PDF (Ukr) 313K

1. Chernyshova TE, Kurnykova YA, Maslova YS. Dysplaziya soedinitelnoy tkani: prognosticheskoe znachenie v diabetologyi [Connective tissue dysplasia: prognostic value in diabetology]. Kuban nauch medytsin vestnik (Barnaul). 2009; 6(111): 76–79. [Russian]
2. Nefrologiya: rukovodstvo dlya vrachey [Nephrology: A Guide for Physicians.]. Pod red YE Tareevoy. M: Meditsina, 2000. 688 p. [Russian]
3. Bondar YA, Klimontov VV. Tubulointerstitsialnyi fibroz pri diabeticheskoy nefropatii: mekhanizmy razvitiya i podkhody k lecheniyu [Tubulointerstitial fibrosis in diabetic nephropathy: mechanisms of development and approaches to treatment]. Nefrologyya. 2008; 2: 11-15. [Russian]
4. Shrikanth CB, Sanjana J, Nandini CD. AMPK differentially alters sulfated glycosaminoglycans under normal and high glucose milieu in proximal tubular cells. J Biochem. 2020; Aug 12: mvaa094. https://doi.org/10.1093/jb/mvaa094
5. Kameneva EA. Sulfatirovannue glikozaminoglikany kak markery porazheniya sosudistoy stenki pri sakharnom diabete [Sulfated glycosaminoglycans as markers of vascular wall damage in diabetes mellitus]. Materyaly vtorogo natsyonalnogo kongressa terapevtov. M; 2007. 342 p. [Russian]
6. Babaeva AR, Kameneva EA, Zakharina OA. Syvorotochnye glikozaminoglikany i antitela k nim kak markery sosudistykh porazheniy pri sakharnom diabete [Serum glycosaminoglycans and antibodies as markers of vascular lesions in diabetes mellitus]. Vestnyk Volgograd gos med. un-ta. 2008; 2: 50-53. [Russian]
7. Van der Vlag J, Buijsers B. Heparanase in Kidney Disease. Adv Exp Med Biol. 2020; 1221: 647-667. https://doi.org/10.1007/978-3-030-34521-1_26
8. Talsma DT, Katta K, Ettema MB, Kel B, Kusche-Gullberg M, Daha MR, el al. Endothelial heparan sulfate deficiency reduces inflammation and fibrosis in murine diabetic nephropathy. Lab Invest. 2018; 98(4): 427-438. https://doi.org/10.1038/s41374-017-0015-2
9. Yokoyama H, Sato K, Okudaira M. Serum and urinary concentrations of heparansulfate in patients with diabetic nephropathy. Kidney Int. 1999; 56(2): 650-658.
10. Krop M, Van Gool JM, Day D, Hollenberg NK, Jan Danser AH. Evaluation of a direct prorenin assay making use of a monoclonal antibody directed against residues 32–39 of the prosegment. J Hypertens. 2011; 29(11): 2138-2146.
11. Klimontov VV, Bondar IA, Nadeev AP. Biokhimicheskie i morfologicheskie markery glomeruloskleroza u bolnykh s doklinicheskimi stadiyami diabeticheskoy nefropatiy [Biochemical and morphological markers of glomerulosclerosis in patients with preclinical stages of diabetic nephropathy]. Materyaly 3-go Vserossiyskogo diabetologicheskogo kongressa. M; 2004. 480 p. [Russian]
12. Alsaad KO, Edrees B, Rahim KA, Alanazi A, Ahmad M, Aloudah N. Collagenofibrotic (Collagen Type III) glomerulopathy in association with diabetic nephropathy. Saudi J Kidney Dis Transpl. 2017; 28(4): 898-905.
13. Tamsma JT, van den Born J, Bruijn JA, Assmann KJ, Weening JJ, Berden JH, et al. Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulphate in the glomerular basement membrane. Diabetologia. 1994; 37(3): 313-320.
14. Klimontov VV, Bondar IA. Izmeneniya metabolizma kollagena pri diabeticheskoy nefropatiy [Collagen metabolism changes in diabetic nephropathy]. Problemy endokrinologii. 2005; 2: 23-28. [Russian]
15. Lepedda AJ, De Muro P, Capobianco G, Formato M. Significance of urinary glycosaminoglycans / proteoglycans in the evaluation of type 1 and type 2 diabetes complications. J Diabetes Complications. 2017; 31(1): 149-155. https://doi.org/10.1016/j.jdiacomp.2016.10.013
16. Paul GA, Rusova TA. Opredelenie sulfatirovannykh glikozaminoglikanov v moche [Determination of sulfated glycosaminoglycans in urine]. Klynycheskaya laboratornaya dyagnostyka. 1995; 2: 13-14. [Russian]
17. Klimontov V, Bondar I, Paul G. Serum activity of lysosomal enzymes and urinary glycosaminoglycan excretion in diabetic nephropathy. Diabetologia. 2001; 44(1): 269.
18. Lepedda AJ, De Muro P, Capobianco G, Formato MJ. Significance of urinary glycosaminoglycans/proteoglycans in the evaluation of type 1 and type 2 diabetes complications. Diabetes Complications. 2017; 31(1): 149–155. https://doi.org/10.1016/j.jdiacomp.2016.10.013
19. Bondar IA, Klimontov VV, Paul GA. Obmen sulfatirovannykh glikozaminoglikanov i aktivnost lizosomnykh fermentov u bolnykh s diabeticheskoy nefropatiey [Metabolism of sulfated glycosaminoglycans and the activity of lysosomal enzymes in patients with diabetic nephropathy]. Sakharnyi diabet. 2002; 1: 46-49. [Russian]
20. Masola V, Gambaro G, Tibaldi E, Onisto M, Abaterusso C, Lupo A. Regulation of heparanase by albumin and advanced glycation and products in proximal tubular cells. Biochim Biophys Acta. 2011; 1813(8): 1475-1482. https://doi.org/10.1016/j.bbamcr.2011.05.004
21. Klimontov VV, Bondar IA, Paul GA. Ekskretsiya sulfatirovannykh glikozaminoglikanov s mochoy u bolnykh s diabeticheskoy nefropatiey [Urinary excretion of sulfated glycosaminoglycans in patients with diabetic nephropathy]. Problemy endokrynologyy. 2001; 4: 35-38. [Russian]
22. Klimontov VV, Bondar IA, Paul GA. Obmen sulfatirovannykh glikozaminoglikanov u bolnykh s diabeticheskoy nefropatiey. Aktualnye problemy sovremennoy endokrinologyi [Metabolism of sulfated glycosaminoglycans in patients with diabetic nephropathy]. Materyaly IV Vserossiyskogo kongressa endokrinologov (SPb). SPb; 2001. p. 94. [Russian]
23. Klimontov VV, Bondar IA, Paul GA. Obmen glikozaminoglikanov i aktivnost lizosomalnykh fermentov u bolnykh s diabeticheskoy nefropatiey [Glycosaminoglycan metabolism and activity of lysosomal enzymes in patients with diabetic nephropathy]. Sakharnyi diabet. 2002; 1: 46-49. [Russian]
24. Lewis EJ, Xu X. Abnormal glomerular permeability characteristics in diabetic nephropathy: implications for the therapeutic use of low-molecular weight heparin. Diabetes Care. 2008; 31: 202-207.
25. Liu YN, Zhou J, Li T, Wu J, Wu J, Xie SH, Liu HF, et al. Sulodexide Protects Renal Tubular Epithelial Cells from Oxidative Stress-Induced Injury via Upregulating Klotho Expression at an Early Stage of Diabetic Kidney Disease. J Diabetes Res. 2017; 2017: 4989847. https://doi.org/10.1155/2017/4989847
26. Born van den J, Pisa B, Bakker MA. No change in glomerular heparansulfate structure in early human and experimental diabetic nephropathy. J Biol Chem. 2006; 281(40): 606-613.
27. Rügheimer L, Carlsson C, Johnsson C. Renal hyaluronan content during experimental uncontrolled diabetes in rats. J Physiol Pharmacol. 2008; 59(1): 115-128.
28. Lewis A, Steadman R, Manley P. Diabetic nephropathy, inflammation, hyaluronan and interstitial fibrosis. Histol and histopathol. 2008; 23(6): 731-739.
29. Klimontov VV, Bondar IA, Kim LB. Uroven fibronektina v syvorotke krovi u bolnykh sakharnym diabetom tipa 1 [Serum fibronectin levels in patients with type 1 diabetes mellitus]. Aktualnye problemy sovremennoy endokrinologii: materialy mezhregionalnoy konferentsii, posvyashchennoy 70-letiyu Novosib gos med. akad. Novosibirsk; 2005. p. 77-78. [Russian]
30. Kim LB, Kulikov VYu, Aslamova SA. Aktivnost reaktsii perekisnogo okisleniya lipidov i soderzhanie glikozaminoglikanov u bolnykh sakharnym diabetom pervogo tipa s diabeticheskoy nefropatiey [Activity of lipid peroxidation reactions and the content of glycosaminoglycans in patients with type 1 diabetes mellitus with diabetic nephropathy]. Byulleten Sibir. otdeleniya RAMN (Novosibirsk). 2005; 3(117): 83-86. [Russian]